TITLE

GPC BIOTECH MARKETING AUTHORIZATION APPLICATION WITHDRAWN

PUB. DATE
September 2008
SOURCE
Worldwide Biotech;Sep2008, Vol. 20 Issue 9, p5
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports on the plan of GPC Biotech's partner for satraplatin in Europe to withdraw the Marketing Authorization Application (MAA) for the drug plus prednisone for the treatment of hormone-refractory prostate cancer patients. Such decision was based on a list of outstanding issues received after a review was conducted by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA).
ACCESSION #
34073780

 

Related Articles

  • GPC Biotech to withdraw marketing application for satraplatin.  // PharmaWatch: Biotechnology;Sep2008, Vol. 7 Issue 9, p11 

    The article reports on the plan of GPC Biotech AG to withdraw the marketing authorization application for satraplatin due to its failure to treat hormone-refractory prostate cancer in Europe. The initiative was based on the disapproval of the Committee for Medicinal Products for Human Use of the...

  • Celgene Calls it Quits in GPC Satraplatin Deal. Young, Donna // BioWorld Today;8/8/2008, Vol. 19 Issue 154, p1 

    The article reports on the ending of the partnership established by Celgene Corp. with GPC Biotech AG for its prostate cancer drug satraplatin. Celgene has retracted its European marketing application for the drug, which is combined with prednisone to manage prostate cancer. GPC reveals that its...

  • American Society of Clinical Oncology.  // BioWorld Today;6/3/2009, Vol. 20 Issue 105, p5 

    The article highlights the Phase III Satraplatin and Prednisone Against Refractory Cancer (SPARC) trial presented by GPC Biotech AG at the 2009 American Society of Clinical Oncology (ASCO) annual meeting. The trial compares satraplatin plus prednisone and placebo plus prednisone in patients...

  • GPC Biotech expands Satraplatin phase III trial.  // PharmaWatch: Cancer;March 2004, Vol. 3 Issue 3, p13 

    Reports that GPC Biotech received a Scientific Advice letter from the European Agency for the Evaluation of Medicinal Products, enabling it to proceed with its registrational plans in Europe using the Satraplatin and Prednisone Against Refractory Cancer trial. Trial evaluation of Satrapaltin...

  • Spectrum and GPC prostate cancer drug shows promise in vitro.  // PharmaWatch: Cancer;January 2005, Vol. 4 Issue 1, p18 

    Reports that development partners Spectrum Pharmaceuticals Inc. and GPC Biotech AG have presented data on the effect of satraplatin on prostate cancer cell lines. Reduction in prostate-specific antigen (PSA) expression; Tumor cell death.

  • Prostate Cancer Update.  // PharmaWatch: Cancer;Jul2008, Vol. 7 Issue 7, p14 

    The article offers several prostate cancer drug-related updates in 2008. GPC Biotech has received a European patent that is related to satraplatin. Novacea Inc. has announced preliminary findings from its Ascent-2 Phase III clinical trial which compared Asentar in combination with Taxotere...

  • Celgene Calls it Quits in GPC Satraplatin Deal. Young, Donna // BioWorld International;8/13/2008, Vol. 13 Issue 33, p3 

    The article reports that Celgene Corp. has ended its partnership with German firm GPC Biotech AG on its prostate cancer drug satraplatin in August 2008. Said decision was made following Celgene's withdrawal of its European marketing authorization application for satraplatin in combination with...

  • Prostate Cancer News Headlines January 15, 2004--February 14, 2004.  // PharmaWatch: Cancer;March 2004, Vol. 3 Issue 3, p13 

    Presents news briefs concerning prostate cancer treatment, compiled as of February 14, 2004. Expansion of clinical trials for GPC Biotech's Satraplatin drug; Avalon Pharmaceuticals' discovery of prostate cancer biomarker; Celsion's expansion of its ThermoDox prostate cancer study.

  • Spectrum's prostate anticancer drug candidate granted fast track designation.  // PharmaWatch: Cancer;November 2003, Vol. 2 Issue 11, p22 

    Reports that the United States Food and Drug Administration has granted Spectrum Pharmaceuticals Inc. and GPC Biotech AG fast track designation for satraplatin as a second-line treatment for hormone-refractory prostate cancer. Clinical trial evaluating satraplatin plus prednisone versus...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics